Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status.
colon cancer
microsatellite instability
stage II colon cancer
stage III colon cancer
tumor side
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
08
2020
accepted:
28
01
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
17
4
2021
Statut:
epublish
Résumé
Tumor sidedness as a prognostic factor in advanced stage colon cancer (CC) is well established. The impact of tumor sidedness on the clinical outcomes of stage II and III CC has not been well studied. The National Cancer Database (NCDB) was utilized to identify patients with pathological stage II and III primary adenocarcinoma of the colon from 2010 to 2015 using ICD-O-3 morphology and topography codes: 8140-47, 8210-11, 8220-21, 8260-63, 8480-81, 8490 and C18.0, 18.2,18.3, 18.5,18.6, 18.7. Univariate (UVA) and multivariable (MVA) survival analyses and Kaplan-Meier Curves with Log-rank test were utilized to compare overall survival (OS) based on tumor location and treatment received. A total of 35,071 patients with stage II (n = 17,629) and III (n = 17,442) CC were identified. 51.3% female; 81.5% Caucasian; median age 66 (range, 18-90). Majority of stage II and III tumors were right sided, 61.2% (n = 10,794) and 56.0% (n = 9,763). Microsatellite instability high (MSI-H) was more common in stage II compared to III, 23.3% (n = 4,115) Survival was better in left sided tumors compared to right in stage II MSS, stage III MSS, and stage III MSI-H CC.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor sidedness as a prognostic factor in advanced stage colon cancer (CC) is well established. The impact of tumor sidedness on the clinical outcomes of stage II and III CC has not been well studied.
METHODS
METHODS
The National Cancer Database (NCDB) was utilized to identify patients with pathological stage II and III primary adenocarcinoma of the colon from 2010 to 2015 using ICD-O-3 morphology and topography codes: 8140-47, 8210-11, 8220-21, 8260-63, 8480-81, 8490 and C18.0, 18.2,18.3, 18.5,18.6, 18.7. Univariate (UVA) and multivariable (MVA) survival analyses and Kaplan-Meier Curves with Log-rank test were utilized to compare overall survival (OS) based on tumor location and treatment received.
RESULTS
RESULTS
A total of 35,071 patients with stage II (n = 17,629) and III (n = 17,442) CC were identified. 51.3% female; 81.5% Caucasian; median age 66 (range, 18-90). Majority of stage II and III tumors were right sided, 61.2% (n = 10,794) and 56.0% (n = 9,763). Microsatellite instability high (MSI-H) was more common in stage II compared to III, 23.3% (n = 4,115)
CONCLUSION
CONCLUSIONS
Survival was better in left sided tumors compared to right in stage II MSS, stage III MSS, and stage III MSI-H CC.
Identifiants
pubmed: 33859934
doi: 10.3389/fonc.2021.592351
pmc: PMC8042136
doi:
Types de publication
Journal Article
Langues
eng
Pagination
592351Informations de copyright
Copyright © 2021 Akce, Zakka, Jiang, Williamson, Alese, Shaib, Wu, Behera and El-Rayes.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Med Sci. 2017 Feb 1;13(1):157-162
pubmed: 28144267
J Clin Oncol. 2013 Oct 10;31(29):3664-72
pubmed: 24019539
Science. 1993 May 7;260(5109):816-9
pubmed: 8484122
Int J Cancer. 2002 Oct 10;101(5):403-8
pubmed: 12216066
JAMA Oncol. 2017 Feb 1;3(2):194-201
pubmed: 27722750
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Ann Intern Med. 1990 Nov 15;113(10):779-88
pubmed: 2240880
J Clin Oncol. 1999 May;17(5):1356-63
pubmed: 10334519
J BUON. 2018 Dec;23(7):11-18
pubmed: 30722106
J Clin Oncol. 1999 May;17(5):1349-55
pubmed: 10334518
Gastroenterology. 2000 Oct;119(4):921-8
pubmed: 11040179
Cancer Res. 1998 Apr 15;58(8):1713-8
pubmed: 9563488
J Clin Oncol. 2005 Jan 20;23(3):609-18
pubmed: 15659508
J Clin Oncol. 1993 Oct;11(10):1879-87
pubmed: 8410113
Ann Surg Oncol. 2014 Jun;21(6):1781-91
pubmed: 24643898
Am J Pathol. 1994 Jul;145(1):148-56
pubmed: 8030745
Cancer Invest. 2008 Nov;26(9):956-63
pubmed: 18798075
Gut. 2005 Mar;54(3):374-84
pubmed: 15710986
J Clin Oncol. 1999 Nov;17(11):3553-9
pubmed: 10550154
J Natl Compr Canc Netw. 2017 Mar;15(3):411-419
pubmed: 28275039
Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62
pubmed: 12917207
J Clin Oncol. 2009 Feb 20;27(6):872-7
pubmed: 19124803
Mod Pathol. 1994 Feb;7(2):161-5
pubmed: 8008736
World J Gastroenterol. 2015 Jun 7;21(21):6470-8
pubmed: 26074686
N Engl J Med. 2003 Jul 17;349(3):247-57
pubmed: 12867608
J Clin Oncol. 2011 Sep 1;29(25):3381-8
pubmed: 21788561
Ann Surg Oncol. 2008 Sep;15(9):2388-94
pubmed: 18622647
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
Ann Oncol. 2014 May;25(5):1032-8
pubmed: 24585723
Clin Cancer Res. 2007 Jul 1;13(13):3831-9
pubmed: 17606714
J Clin Oncol. 2004 May 15;22(10):1797-806
pubmed: 15067028
Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23
pubmed: 11535541
J Gastrointest Surg. 2016 Mar;20(3):648-55
pubmed: 26573851
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15
pubmed: 18990764
J Surg Oncol. 2004 Dec 15;88(4):261-6
pubmed: 15565587
J Clin Oncol. 2011 Nov 20;29(33):4401-9
pubmed: 21969498
JAMA Oncol. 2017 Feb 1;3(2):211-219
pubmed: 27787550
Dis Colon Rectum. 2010 Jan;53(1):57-64
pubmed: 20010352
J Clin Oncol. 2011 Apr 1;29(10):1261-70
pubmed: 21383284